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Transcriptome 3′end organization by PCF11 links
alternative polyadenylation to formation and
neuronal differentiation of neuroblastoma
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Diversification at the transcriptome 3′end is an important and evolutionarily conserved layer
of gene regulation associated with differentiation and dedifferentiation processes. Here, we
identify extensive transcriptome 3′end-alterations in neuroblastoma, a tumour entity with a
paucity of recurrent somatic mutations and an unusually high frequency of spontaneous
regression. Utilising extensive RNAi-screening we reveal the landscape and drivers of tran-
scriptome 3′end-diversification, discovering PCF11 as critical regulator, directing alternative
polyadenylation (APA) of hundreds of transcripts including a differentiation RNA-operon.
PCF11 shapes inputs converging on WNT-signalling, and governs cell cycle, proliferation,
apoptosis and neurodifferentiation. Postnatal PCF11 down-regulation induces a neurodiffer-
entiation program, and low-level PCF11 in neuroblastoma associates with favourable outcome
and spontaneous tumour regression. Our findings document a critical role for APA in
tumorigenesis and describe a novel mechanism for cell fate reprogramming in neuroblastoma
with potentially important clinical implications. We provide an interactive data repository of
transcriptome-wide APA covering > 170 RNAis, and an APA-network map with regulatory
hubs.
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Neuroblastomas are the most common solid tumour ininfants accounting for ~15% of all cancer deaths in chil-dren. They arise from incompletely committed precursor
cells derived from neural crest tissues, and can present as tumour
lesions in the neck, chest, abdomen or pelvis. The clinical pre-
sentation is heterogeneous, ranging from an asymptomatic
tumour disease to a critical illness as a result of local invasion, or
as widely disseminated disease. Remarkably, this tumour entity is
generally characterised by a lack of recurrent somatic mutations,
and exhibits one of the highest proportions of spontaneous and
complete regression of all human cancers by as yet unknown
mechanisms1,2.
Next-generation RNA sequencing has led to the discovery of
a perplexingly complex metazoan transcriptome architecture
arising from the alternative use of transcription start sites,
exons and introns and polyadenylation sites3,4. The combina-
torial use, and incorporation, of such elements into mature
transcript isoforms considerably expands genomic information
and is subject to dynamic spatial and temporal modulation
during development and adaptation. Recently, diversification of
the transcriptome at the 3′ end through alternative poly-
adenylation (APA) evolved as an important and evolutionarily
conserved layer of gene regulation5. APA results in transcript
isoforms varying at the RNA 3′ end, which can encode proteins
with profoundly distinct functions or regulatory properties.
Furthermore, APA can affect the mRNA fate via the inclusion
or exclusion of regulatory elements6.
Constitutive RNA 3′end maturation relies on a complex
macromolecular machinery, which catalyses endonucleolytic
cleavage and polyadenylation of pre-mRNA molecules7. This
involves the assembly of four multicomponent protein complexes
(CPSF, CSTF, CFIm and CFIIm)8 on the pre-mRNA at dedicated
processing sites9. Differential expression of individual complex
components can direct APA resulting in transcript isoforms with
alternative 3′ ends10,11. In addition, other mechanisms including
epigenetic events can affect APA, illustrating a previously unan-
ticipated complex crosstalk between various cellular processes in
the control of transcriptome diversity12. Interestingly, BARD1,
one of the few factors affected by recurrent somatic mutations in
neuroblastoma13 (beyond MYCN, ALK and PHOX2B)2, forms a
heterodimer with CSTF subcomponents to modulate mRNA 3′
end processing14. Although difficult to detect by standard high-
throughput profiling techniques15, dynamic changes at the tran-
scriptome 3′ end are prevalent16,17 (Fig. 1a). They are often
associated with differentiation and dedifferentiation
processes11,18. However, the underlying mechanisms and func-
tional consequences for development and disease remain poorly
understood19.
Here we identify extensive transcriptome 3′end architecture
alterations during neuroblastoma differentiation. By combining
a genome-wide high-throughput analysis with a comprehensive
RNAi screening targeting more than 170 potential components
involved in the definition of RNA 3′ ends, we delineate the
dynamic landscape of and explore mechanisms influencing
transcriptome 3′end diversification in this tumour entity. We
identify PCF11, a CFIIm complex component involved in
transcription termination and RNA 3′end maturation20,21, as a
critical regulator pervasively directing APA of hundreds of
transcripts in neuroblastoma. By generating and applying an
inducible short hairpin RNA (shRNA) mouse model targeting
PCF11 complemented by studies of neuroblastoma patient
samples, we discover an unexpected critical role for PCF11-
dependent APA regulation in neuronal differentiation with
potentially important implications for spontaneous tumour
regression.
Results
Massively deregulated TREND in neuroblastoma. To explore
the dynamics of transcriptome 3′end diversity (TREND) in the
context of neuroblastoma biology (Fig. 1a) we used a cellular
model system (BE(2)-C), which faithfully recapitulates critical
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Fig. 1 Pervasive alteration of transcriptome 3′end diversification (TREND) in
childhood neuroblastoma. a The genome complexity is considerably
expanded by co- and post-transcriptional processes. Various mechanisms
including alternative polyadenylation (APA) can result in transcriptome 3′
end diversification (TREND) affecting the coding sequence and/or 3′
untranslated regions (UTR). More than 70% of all genes expressed have
alternative 3′ ends, thus shaping the transcriptome complexity to a similar
extent as alternative splicing (95%) or alternative transcription initiation
(65%). b BE(2)-C neuroblastoma model for all-trans retinoic acid (ATRA)
induced neurodifferentiation (scale bar 100 µm). Western blot of molecular
markers reflecting neuronal differentiation in response to ATRA treatment
(mean ± s.e.m. for three replicates, one-sided t-test p-value, *p < 0.05, ***p
< 0.001; cells are stained with an antibody directed against TUBB3 (red),
nuclei are stained with DAPI (blue)). c Differentiation results in a
widespread TREND regulation leading to the expression of lengthened (red)
and shortened (blue) transcript isoforms, mainly affecting the 3′UTR
(‘tandem’; also depicted in the scatter plot on the right) compared to
relatively fewer events affecting the open reading frame (‘internal’; FC fold
change)
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features of this type of malignancy in children. A subset of these
tumours can be differentiated into benign lesions by employing
retinoid drugs (such as all-trans retinoic acid (ATRA)), which is
standard of care in children with high-risk neuroblastoma22.
Exposing BE(2)-C cells to ATRA results in neuronal differentia-
tion phenotypically and molecularly (Fig. 1b). By employing a
tailored approach based on RNA 3′ region extraction and deep
sequencing15, we observed a significant change of transcripts with
alternative 3′ ends upon BE(2)-C differentiation with a trend
towards shorter transcript isoforms, predominantly affecting 3′
untranslated regions (UTRs) (Fig. 1c).
Thus, in neuroblastoma, undifferentiated neuronal cells do not
only display typical properties of malignant tumour cells (i.e.
absence of neurites and MYCN overexpression, Fig. 1b); they also
express a substantial fraction of shortened and lengthened
transcript isoforms compared to a differentiated state. This
invites speculations that deregulated TREND may be functionally
linked to the dynamically regulated programme shown here
(Supplementary Table 1).
PCF11 drives TREND by directing APA in neuroblastoma. We
next sought to identify drivers of TREND in neuroblastoma by
applying RNAi screening coupled to a newly designed high-
throughput sequencing approach suited to capture polyadenylated
transcript 3′ends of numerous experimental conditions in a highly
multiplexed fashion (TRENDseq; Fig. 2a). We depleted 174 pro-
teins including all known factors involved in pre-mRNA 3′end
cleavage and polyadenylation in eukaryotes8 and selected key
factors regulating transcriptional activities, splicing, RNA turnover
and other functions23–32, which could directly or indirectly
modulate TREND (Supplementary Table 2)5. Probing the effi-
ciency of RNAi-mediated depletion revealed a dropout rate (i.e.
poor RNAi effect) below 5% (Supplementary Figure 1b). Applying
TRENDseq, we identified in our screening in total 9168 TREND-
events (out of 20,156 expressed transcripts, Fig. 2b) corresponding
to more than 3600 genes significantly affected by TREND in
neuroblastoma cells (BH-adjusted p-value < 0.05, Fig. 2c). Upon
depletion, almost all tested factors show TREND regulation
(Fig. 2b, c) with key factors affecting up to 1400 genes (e.g.
NUDT21, CPSF6 and PCF11, Supplementary Table 2; average
effect 130 genes). Directly comparing the effects quantitatively and
qualitatively, we observe that (i) TREND is predominantly driven
by components of the RNA 3′end processing machinery (Fig. 2b,
c) and that (ii) their function is mainly non-redundant (Fig. 2c,
Supplementary Figure 2a). However, a significant proportion of
TREND is controlled by components involved in transcription
and other co- and post-transcriptional events (e.g. splicing and
RNA turnover) or epigenetic modification—to a quantitatively
comparable extent as individual splicing factors affect alternative
splicing33. Interestingly, our screening also identifies TREND
regulation to be caused by factors involved in genome surveillance
or known to drive tumour suppressive programmes (e.g. TP53),
and other processes involved in the coupling between oncogenic
signals and 3′end processing (such as BARD114; details on
TREND-affected targets, regulated Gene Ontology (GO) terms
and executing TREND regulators are provided online, TREND-
DB: http://shiny.imbei.uni-mainz.de:3838/trend-db).
Applying a phylostratigraphy approach we find that almost all
transcripts showing a dynamic regulation at the 3′ end are
encoded by ancient genes (gene age > 450 million years), as most
of the executing TREND regulators (Supplementary Figure 2b,c).
Phylogenetically conserved genes control basic processes and are
more likely associated with overt phenotypes when deregulated34.
Interestingly, depletion of numerous TREND regulators results in
TREND of targets enriched with cancer-associated genes. Most of
these TREND regulators belong to the RNA cleavage and
polyadenylation machinery (p= 0.0195), while other functional
categories (as a whole) are not significantly enriched (Fig. 2c
(inlet), Supplementary Table 3). This suggests that cleavage and
polyadenylation factors control TREND in a conserved manner
with several of them potentially playing important roles in cancer.
Among the top three drivers of TREND, which regulate several
hundreds of genes (Supplementary Table 2), we identify
components of the CFIm and CFIIm complexes (CPSF6,
NUDT21 and PCF11) belonging to the RNA 3′end cleavage
and polyadenylation machinery35 (Fig. 2b, c). Interestingly,
unlike the depletion of many other factors screened, their
depletion directs TREND in an almost exclusive unidirectional
manner resulting in uniformly shortened (CPSF6 and NUDT21)
or lengthened (PCF11) transcript isoforms compared to control
knockdowns (Supplementary Figure 2d). Thus, in (undifferen-
tiated) neuroblastoma PCF11 promotes proximal polyadenylation
site choice, while CPSF6 and NUDT21 facilitate processing at
distal polyadenylation sites.
To further explore the functional hierarchy of TREND-
regulators we made use of the high reproducibility of TRENDseq
(Supplementary Figure 3a). This allowed us to construct a high-
confidence network of TREND-regulators (‘APA-network map’)
to visualise their synergistic and antagonistic actions (considering
the genes affected and directionality of transcript isoform
regulation i.e. shortening or lengthening; Supplementary Fig-
ure 3b). Remarkably, the clustering observed in this analysis
corresponds to known protein complexes involved in RNA
processing8. Further it uncovers a strong antagonistic effect
between NUDT21 and CPSF6 (CFIm components) and PCF11
(CFIIm complex component). This suggests that they play an
important regulatory role in the global organisation of the
transcriptome 3′ end in neuroblastoma. Aberrant expression of
these components can thus lead to profound TREND-
perturbations by affecting APA most quantitatively.
To further define the role of TREND-regulators in the clinically
relevant context studied here, we examined their regulation in
neuroblastoma upon ATRA differentiation. We probed the
protein abundances of all 3′end processing factors and further
key candidates by western blotting. Among 82 proteins profiled
(Supplementary Figure 4) we observe PCF11 to be most strongly
affected (that is a 1.9-fold downregulation upon differentiation,
Fig. 3a) compared to other potent TREND-regulators (e.g.
NUDT21 and CPSF6). Notably, co-depletion of PCF11 together
with other key TREND-regulators establishes PCF11 as a
dominant factor in the functional hierarchy of transcriptome 3′
end diversification (Supplementary Figure 5a). PCF11 acts as a
dominant repressor of APA at distal sites (i.e. promotes
processing at proximal sites), and counteracts the repression of
APA at proximal sites executed by CPSF6. Accordingly, PCF11
depletion leads to massive lengthening of the transcriptome,
predominantly by de novo activation of previously un-annotated
polyadenylation sites far downstream in the 3′ flanking sequence
(Supplementary Figure 3a,c). PCF11-directed APA thereby results
in a significant production of transcript isoforms harbouring
‘new’ regulatory elements in their 3′ UTRs (such as miRNA- or
RBP-binding sites). This in turn can influence important cellular
functions e.g. by modulating the protein output of the affected
target RNAs36–38. Altogether, PCF11 thus represents a global key
driver of TREND by directing APA in the BE(2)-C neuroblas-
toma model system in a direct and most efficient manner (Fig. 3a,
Supplementary Figure 5a-c); PCF11 downregulation reshapes the
transcriptome 3′end architecture reminiscent to that observed in
mature neurons that typically show a more prevalent expression
of long transcript isoforms39 (Fig. 2b, c, Supplementary Figure 3c).
However, we also note that PCF11 is likely not the only factor
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regulated during neurodifferentiation (Fig. 3a). This corresponds
to the mixed TREND-pattern of transcript lengthening and
shortening during neurodifferentiation in the simplistic neuro-
blastoma BE(2)-C model (Fig. 1c).
PCF11-directed APA controls WNT and neurodifferentiation.
The pervasive mode of PCF11 in directing TREND suggests an
important role in basic cellular programmes, including a potential
function in tumorigenesis (Supplementary Table 2, cancer
enrichment score 2.98 × 10−9, Supplementary Figure 6a). To
further substantiate this in the context of neuroblastomas, we
profiled the proteome of BE(2)-C cells upon PCF11-depletion
using mass spectrometry. We identified 5903 proteins out of
which 330 showed a regulation of more than 1.5-fold (p-value <
0.05). Merging this with the data set of APA-regulated transcripts
ba
BarcodeIlluminaT7
Promoter 5′-adapter
Sample-1 Sample-2 Sample-N
A
A
A
A
A
A
TTTTTT
A
A
A
A
A
A
TTTTTT
A
A
A
A
A
A
TTTTTT
Samples pool &
in vitro transcription
RNA fragmentation &
size selection
3′-adapter ligation,
reverse transcription & PCR
d(T)25-anchor
Illumina sequencing
Read 1
Read 2
Read 1 – In-lane barcode
Read 2 – RNA insert sequence
Demultiplexing
Trimming
& filtering
Mapping to genome
Analysis of 3′end diversity:
Raw data
Fisher’s exact test for each
TREND isoform 
Shortening index
GO analysis
TREND database
0 0.1 0.2 0.3 0.4 0.5 0.7 0.9 1.1 1.3
CTDP1
SSU72
PIN1
CDK7
CDK9
CDK8
WDR61
CDC73
CTR9
LEO1
PAF1
NRF1
MEF2D
E2F4
TBP
GTF2I
POLR2J
POLR2E
POLR2C
POLR2B
POLR2A
CTCF
YBX1
TTF2
PABPC1
PABPN1
PABPC4
PAPD7
PAPD5
PAPD4
PAPOLG
PAPOLA
CPEB1
RBBP6
WDR33
CSTF2T
SYMPK
CPSF3L
CLP1
PCF11
NUDT21
CPSF7
CPSF6
CSTF3
CSTF2
CSTF1
FIP1L1
CPSF4
CPSF3
CPSF2
CPSF1
Internal
Tandem
Novel
Non-Coding
0 20 40 60 80 100
% of 20,156 TREND-isoforms
Discovered Altered
0 20 40 60 80 100
% of 9168 TREND-isoforms
Cleavage and polyadenylation
Transcription
RNAsplicing
RNAturnover
Translation
Cell cycle & Replication
Epigenetics
Genome surveillance
Cancer associated
Apoptosis
Others
Internal shortening
Internal lengthening
Tandem shortening
Tandem lengthening
Novel shortening
Novel lengthening
Non-coding shortening
Non-coding lengthening
TREND type
CIRBP
GNB2L1
EIF4G1
EIF4A1
EIF4E
EIF3C
EIF2A
ZFP36
DCP1A
ExosC6
SKIV2L
EXOSC10
DIS3L
DIS3
CNOT2
CASC3
SMG6
ALYREF
RNPS1
UPF3B
UPF3A
UPF2
UPF1
DCP2
TTC37
SKIV2L2
TNRC6A
CNOT7
XRN2
XRN1
Nova2
SCAF1
DDX39B
RBM5
SRSF4
SRSF3
CDC40
SRRM2
SRRM1
SNRPA
SNRNP48
SNRPA1
SNRNP70
SF3A1
DDX23
ZCCHC8
SF1
SRSF1
SF3B1
SFPQ
NONO
HNRNPH3
HNRNPH2
HNRNPH1
HNRNPF
HNRNPA2B1
PTBP1
U2AF2
U2AF1
0 0.1 0.2 0.3 0.4
Absolute number of TREND events for each KD, in 103
FUBP3
KHSRP
IGF2BP1
NusA
IFIT3
IFIT1
RBM7
MORF4
JUP
AHCYL1
MAPK14
MAPK9
MAPK8
MAPK3
MAPK1
AGO2
TARBP2
DICER1
NCBP1
SETX
PPP1R10
PPP1CB
PPP1CA
CASP3
BCL2
ELAVL1
TIAL1
TIA1
XPO4
DDX42
DDX20
CDKN2D
CDKN2A
TP53
MYC
SND1
BARD1
TERT
XRCC6
XRCC5
PRKDC
SUPT16H
RBL2
CHD2
CHD1
SMARCA4
KAT2B
SETD2
SETD1B
SETD1A
SLBP
PARN
TUT1
DNMT3B
DNMT3A
TRDMT1
DNMT1
BTG2
CCNB1
NRD1
CDK2
PCNA
RPA3
RPA1
0 0.1 0.2 0.3 0.4 0.5
C
P
S
F
1
C
P
S
F
2
C
P
S
F
3
C
P
S
F
4
F
IP
1L
1
C
S
T
F
1
C
S
T
F
2
C
S
T
F
3
C
P
S
F
6
C
P
S
F
7
N
U
D
T
21
P
C
F
11
C
LP
1
C
P
S
F
3L
S
Y
M
P
K
C
S
T
F
2T
W
D
R
33
R
B
B
P
6
C
P
E
B
1
P
A
P
O
LA
P
A
P
O
LG
P
A
P
D
4
P
A
P
D
5
P
A
P
D
7
P
A
B
P
C
4
P
A
B
P
N
1
P
A
B
P
C
1
T
T
F
2
Y
B
X
1
C
T
C
F
P
O
LR
2A
P
O
LR
2B
P
O
LR
2C
P
O
LR
2E
P
O
LR
2J
G
T
F
2I
T
B
P
E
2F
4
M
E
F
2D
N
R
F
1
P
A
F
1
LE
O
1
C
T
R
9
C
D
C
73
W
D
R
61
C
D
K
8
C
D
K
9
C
D
K
7
P
IN
1
S
S
U
72
C
T
D
P
1
U
2A
F
1
U
2A
F
2
P
T
B
P
1
H
N
R
N
P
A
2B
1
H
N
R
N
P
F
H
N
R
N
P
H
1
H
N
R
N
P
H
2
H
N
R
N
P
H
3
N
O
N
O
S
F
P
Q
S
F
3B
1
S
R
S
F
1
S
F
1
Z
C
C
H
C
8
D
D
X
23
S
F
3A
1
S
N
R
N
P
70
S
N
R
P
A
1
S
N
R
N
P
48
S
N
R
P
A
S
R
R
M
1
S
R
R
M
2
C
D
C
40
S
R
S
F
3
S
R
S
F
4
R
B
M
5
D
D
X
39
B
S
C
A
F
1
N
ov
a2
X
R
N
1
X
R
N
2
C
N
O
T
7
T
N
R
C
6A
S
K
IV
2L
2
T
T
C
37
D
C
P
2
U
P
F
1
U
P
F
2
U
P
F
3A
U
P
F
3B
R
N
P
S
1
A
LY
R
E
F
S
M
G
6
C
A
S
C
3
C
N
O
T
2
D
IS
3
D
IS
3L
E
X
O
S
C
10
S
K
IV
2L
E
xo
sC
6
D
C
P
1A
Z
F
P
36
E
IF
2A
E
IF
3C
E
IF
4E
E
IF
4A
1
E
IF
4G
1
G
N
B
2L
1
C
IR
B
P
R
P
A
1
R
P
A
3
P
C
N
A
C
D
K
2
N
R
D
1
C
C
N
B
1
B
T
G
2
D
N
M
T
1
T
R
D
M
T
1
D
N
M
T
3A
D
N
M
T
3B
T
U
T
1
P
A
R
N
S
LB
P
S
E
T
D
1A
S
E
T
D
1B
S
E
T
D
2
K
A
T
2B
S
M
A
R
C
A
4
C
H
D
1
C
H
D
2
R
B
L2
S
U
P
T
16
H
P
R
K
D
C
X
R
C
C
5
X
R
C
C
6
T
E
R
T
B
A
R
D
1
S
N
D
1
M
Y
C
T
P
53
C
D
K
N
2A
C
D
K
N
2D
D
D
X
20
D
D
X
42
X
P
O
4
T
IA
1
T
IA
L1
E
LA
V
L1
B
C
L2
C
A
S
P
3
P
P
P
1C
A
P
P
P
1C
B
P
P
P
1R
10
S
E
T
X
N
C
B
P
1
D
IC
E
R
1
T
A
R
B
P
2
A
G
O
2
M
A
P
K
1
M
A
P
K
3
M
A
P
K
8
M
A
P
K
9
M
A
P
K
14
A
H
C
Y
L1
JU
P
M
O
R
F
4
R
B
M
7
IF
IT
1
IF
IT
3
N
us
A
IG
F
2B
P
1
K
H
S
R
P
F
U
B
P
3
36
56
 g
en
es
P
C
F
11
 K
D
C
P
S
F
6 
K
D
Log2 shortening index
–1 –0.5 0 10.5
N
U
D
T
21
 K
D
Cleavage and polyadenylation
Transcription
RNAsplicing
RNAturnover
Translation
Cell cycle & Replication
Epigenetics
Genome surveillance
Cancer associated
Apoptosis
Others
Enriched with cancer
Not enriched with cancer
71103522
All factors
Cleavage and
polyadenylation
c
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-018-07580-5
4 NATURE COMMUNICATIONS |          (2018) 9:5331 | https://doi.org/10.1038/s41467-018-07580-5 | www.nature.com/naturecommunications
upon PCF11 depletion, we observed 54 regulated genes (Sup-
plementary Table 4) enriched in GO terms related to ‘neuro-
differentiation’ (Fig. 3b). Thus, PCF11 depletion regulates APA
and protein output of a module of transcripts controlling features
of the cellular process i.e. neurodifferentiation, in which we
observed the downmodulation of PCF11 (Fig. 3a).
We next validated representative APA-affected targets reflect-
ing the discovered signalling pathways and GO terms (Fig. 3b,
Supplementary Figure 6a). We focused on targets that (i) are
involved in neuronal and brain development (IGF1R40), (ii) have
previously been associated with signal transduction in neural cells
or neuroblastoma regression (AES, GNB141) or (iii) play a role in
other pathways more globally involved in tumorigenesis and the
endoplasmic reticulum (ER) stress response (EIF2 signalling). We
observed that PCF11-directed APA results in a significant
upregulation of IGF1R, EIF2S1 and AES protein abundance,
while GNB1 is downregulated upon PCF11 depletion (Fig. 4a).
These changes are likely functional as we also noted the expected
downstream alterations of the IGF1R, PI3K/Akt and ER stress
response signalling pathways. In addition, some of the observed
changes upon PCF11 depletion (i.e. activation of the PI3K/Akt
pathway) are surprisingly consistent with their reported role for
neuroblastoma differentiation42. Most notably however, all four
validated APA-affected targets (IGF1R, EIF2S1, AES and GNB1)
constitute a highly enriched protein interaction network imping-
ing on WNT signalling (i.e. beta-catenin (CTNNB1), p-value
1.86 × 10−4, Fig. 4b). This is consistent with the predicted
function of the entire set of APA-affected target genes regulated
by PCF11 depletion, which show a role in WNT signalling
(Supplementary Figure 6a).
PCF11-directed APA drives neuroblastoma differentiation.
WNT signalling is essential for embryonic development and cell
fate specification by executing various programmes43. We
therefore studied whether depletion of PCF11 ‘translates’ into
functional alterations of the WNT pathway and associated cel-
lular programmes. To this end, we generated stable cell lines
expressing an Isopropyl β-D-1-thiogalactopyranoside (IPTG)-
inducible shRNA against PCF11 (further details see Methods
section). Interestingly, PCF11 depletion abrogates WNT signal-
ling in reporter assays (Fig. 4c), and results in cell cycle retar-
dation, increased rate of apoptosis, reduced cell proliferation
(Fig. 4d–f, Supplementary Figure 6b) and ultimately differentia-
tion of neuroblastoma (Fig. 4g). Importantly, this effect is not
limited to the BE(2)-C cell model and similar results were
obtained in CHP-134 neuroblastoma cells (Supplementary Fig-
ure 6c). Thus, PCF11 depletion mimics an ATRA-induced neu-
rodifferentiation phenotype, which is associated with the
activation of essential pathways for neuroblastoma differentiation
(Fig. 4a)42. Vice versa, constitutive overexpression of PCF11
inhibits ATRA-induced neurodifferentiation (Supplementary
Figure 6d).
Based on these observations linking PCF11 to hallmark
features of cancer, we hypothesised that PCF11 may determine
a malignant phenotype. In order to assess this further, we used
stable cell lines expressing an IPTG-inducible shRNA against
PCF11 (see above). Indeed, depletion of PCF11 abolished colony
formation, reduced cell invasiveness and resulted in retarded
tumour growth in a neuroblastoma xenograft model (Fig. 5a–c).
This recapitulates our findings obtained with the BE(2)-C and
CHP-134 neuroblastoma models (Fig. 4d–g, Supplementary
Figure 6c) and corroborates an important role of PCF11 in
tumour fate specification.
Neuroblastomas originate from incompletely committed sym-
pathetic neural precursor cells. We thus reasoned that PCF11
expression may specify distinct developmental stages. Mirroring
PCF11 downregulation during neuronal differentiation (Fig. 3a),
we also observed significantly higher PCF11 expression prenatally
compared to postnatal human and murine brain samples (p-
value < 8.1 × 10−17; Supplementary Figure 7a,b). Accordingly,
mature brain tissues show a significant TREND-lengthening
phenotype compared to embryonic stem (ES) cells (Supplemen-
tary Figure 7c) including all four representative transcripts from
the APA-affected module with a role in neurodifferentiation
(GNB1, AES, IGF1R and EIF2S1; Fig. 4b). Thus, although
neuroblastomas derive from sympathetic nervous system pre-
cursor cells, it appears that they share neurodevelopmental
features with neurons in the central nervous system with PCF11-
dependent APA regulation being an important mechanism in this
process.
To further corroborate the role of PCF11 for APA and
neurodifferentiation, we generated a transgenic TET-inducible
PCF11-shRNA mouse model (further details see Methods
section). Briefly, in this model system doxycycline supplementa-
tion induces the expression of a shRNA designed to specifically
ablate PCF11 expression (Fig. 5d, upper panel). Using this system,
we observed APA with a predominating transcript lengthening
phenotype upon PCF11 depletion in ES cells and, to a lesser
extent, as expected, in mature brain samples (Fig. 5d, lower
panel). Strikingly, PCF11 depletion in primary murine neurons
(E18) obtained from the central nervous system of these animals
led to neurodifferentiation (Fig. 5e), which is consistent with the
neurodifferentiation phenotype upon depletion of PCF11 in the
BE(2)-C and CHP-134 model system (Fig. 4g, Supplementary
Figure 6c). Thus, although BE(2)-C and CHP-134 represent only
one of the three genetic subgroups of neuroblastoma (i.e. high-
risk MYCN amplified tumours), our data indicate that this
phenomenon is not confined to MYCN amplified cells nor
Fig. 2 Massive RNAi screening reveals key regulators of TREND in neuroblastoma with a potential role in tumorigenesis. a TRENDseq library preparation
(top) and bioinformatical pipeline (bottom) for highly multiplexed genome-wide analysis of the TREND-landscape. The Integrated Genomics Viewer (IGV)
of two sequence read alignments (lower right corner) illustrates two distinct TREND-phenotypes that correspond to a more prevalent distal (condition
shown in red; reflecting ‘lengthening’ compared to the respective other condition) or proximal polyadenylation (condition shown in blue; reflecting
‘shortening’ compared to the respective other condition), respectively. b Relative proportion of TREND types discovered in neuroblastoma BE(2)-C (upper
left diagram), and isoforms effectively altered upon RNAi depletion of at least 1 out of 174 putative TREND regulators (upper right diagram). ‘Tandem’ and
‘Internal’ events affect annotated 3′ UTRs or protein C termini, ‘Novel’ assign transcript isoforms exceeding the annotated gene 3′ end and ‘Non-coding’
depict TREND alterations affecting non-coding RNAs. Individual TREND regulation per RNAi candidate is shown in the bar diagram (the colour code
indicates the functional category to which the depleted factor belongs to, see also Supplementary Table 2). c Landscape of TREND upon RNAi (KD
knockdown) of 174 individual putative TREND regulators (x-axis; functional categories to which the RNAi candidates belong to are the same indicated for
b; see Supplementary Figure 2a). Each spot in the heat map reflects a gene significantly affected by TREND (the colour code in the heat map indicates the
directionality of TREND; for example, a negative shortening index indicates a relatively more prevalent lengthened transcript isoform expressed by the
respective gene upon depletion of the respective TREND regulator). Inlet: pie chart showing overrepresentation of cancer-associated genes affected by
TREND upon depletion of 3′end processing components (for individual p-values see Supplementary Table 3)
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restricted to neuroblastoma. This suggests a more global role of
PCF11 in coordinating the timely switch to fully committed
neuronal fate (Figs. 4g and 5e) thereby preventing uncontrolled
embryonic proliferative programmes that may eventually give rise
to neuroblastic tumours.
PCF11 links APA to spontaneous tumour regression. We next
explored whether these findings obtained with various cell models
can be generalised and ‘translate’ into a clinical phenotype. To
this end, we made use of a previously thoroughly validated cohort
of 498 neuroblastoma samples44. In this data set we observed a
significantly more adverse outcome in patients showing high-level
compared to low-level PCF11 expression (BH-adjusted p-value:
0.00275; Fig. 5f). In light of PCF11 controlling APA of a module
of transcripts associated with neurodifferentiation (Fig. 3b), we
speculated that the expression of PCF11 may be associated with
spontaneous neuroblastoma regression. Although metastatic,
stage 4S neuroblastomas diagnosed in children <12 months show
an excellent prognosis (approximately 90% survival) even without
chemotherapy due to a high rate of spontaneous tumour
regression. In contrast, stage 4 neuroblastomas displaying an
almost comparable metastatic spread rarely regress and have a
poor outcome (30–50% survival) despite intensive multimodal
therapy45. When comparing stage 4S with stage 4 neuro-
blastomas, we identified a significantly higher PCF11 expression
in the latter (p-value= 1.15 × 10−6, Fig. 5g). Furthermore, low-
level PCF11 expression also appears to be unique for stage 4S
when compared to the localised stage 1 or 2 (that normally do not
spontaneously regress; Supplementary Figure 7d). Thus, low-level
PCF11 is associated with a better outcome and possibly a greater
likelihood for spontaneous tumour regression. This reflects our
in vitro and in vivo observations (Figs. 4c–g and 5a–e, Supple-
mentary Figure 6a–e) and is corroborated by the respective
expression signature of established markers for spontaneous
neuroblastoma regression (that is a higher expression of
HOXC946 and CHD547, Fig. 5g), although further studies are
required to more comprehensively illuminate the role of PCF11
in this process.
In view of the central role of PCF11 for neurodifferentiation
(Figs. 4g and 5e, Supplementary Figure 6c), for the regulation of
APA of a neurodifferentiation operon (Fig. 3b) and the
association with neuroblastoma prognosis (Fig. 5f, including
high-risk neuroblastomas, Fig. 6a), we expected to identify
corresponding TREND alterations in neuroblastoma patients,
which mirror this functional association. To this end, we
programmed a bioinformatic pipeline suited to extract transcript
isoforms from conventional mRNA expression array data and
queried the fraction and identity of transcripts differing at the 3′
end. Indeed, we identified a high prevalence of transcript
lengthening (332 genes vs. 93 genes showing transcript short-
ening) in conditions with low- (stage 4S) compared to high-level
PCF11 expression (stage 4; Fig. 6b). This is reminiscent to the
TREND phenotype showing mostly a switch to longer transcript
isoforms after PCF11 depletion (in vitro and in vivo, Figs. 2b, c
and 5d). We further identified a substantial fraction of APA-
affected genes (n= 74) that are shared in the clinical cohort (stage
4S vs. 4; Fig. 6b) with those regulated upon PCF11 depletion in
BE(2)-C cells (hyper-geometric test of enrichment p-value=
0.004; Supplementary Table 5). Surprisingly, this also extends to
17 out of 26 detectable APA-affected genes belonging to the
neurodifferentiation module identified in the PCF11-depletion
setup (Figs. 3b and 4a), including AES, IGF1R and GNB1
(Fig. 6b). Specifically, the relative lengthening of the transcript
isoforms encoding GNB1, a critical modulator of various
transmembrane signalling pathways48, is significantly associated
with a better clinical outcome in neuroblastoma patients (Fig. 6c).
Thus, in line with our observations in the reductionist BE(2)-C
cell model system (Figs. 2–4 and 5a–c), this finding corroborates
the dominant nature of PCF11 in regulating APA in neuro-
blastoma specimens (compared to other potential APA regulators
(Figs. 2 and 3)). It also suggests a potential oncogenic function of
deregulated APA in this tumour entity.
APA of GNB1 is central to PCF11-driven neurodifferentiation.
3′end diversification can have profound physiological effects by
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resulting in mRNAs encoding proteins with distinct functions or
regulatory properties or by affecting the mRNA fate via the
inclusion or exclusion of regulatory elements6. However,
expression modulation of key factors involved in RNA metabo-
lism, such as PCF11, can have pleiotropic and/or indirect effects
(unrelated to APA) that may contribute to the phenotypes
observed in this study. To further substantiate the direct role of
PCF11-directed APA for neurodifferentiation, we explored the
function of GNB1 3′end transcript isoforms in this process. To
this end, we used luciferase reporter assays allowing to study the
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effect of the long and short GNB1 3′ UTR on protein output
(Fig. 6d). Consistent with GNB1 transcript lengthening and lower
GNB1 protein expression following PCF11 downregulation
(Fig. 4a), the long GNB1 transcript isoform appears to harbour a
repressive element residing in the long 3′ UTR that reduces
GNB1 protein expression (Fig. 6d). In contrast, the short isoform
is more efficiently translated, which corresponds to high-level
GNB1 protein expression in the presence of PCF11 (Fig. 4a).
We next performed combinatorial depletion experiments to
selectively manipulate the abundance of GNB1 transcript iso-
forms and to disentangle their function. To this end, we used a
stable BE(2)-C line expressing an IPTG-inducible shRNA against
PCF11 (Fig. 5a–c) and specifically depleted the long GNB1
transcript isoform under conditions with and without IPTG
supplementation (Fig. 6e). While PCF11 depletion induced GNB1
transcript lengthening, downmodulation of GNB1 protein and
neurodifferentiation (Fig. 6e, f), co-depletion of the long GNB1
transcript isoform restored GNB1 protein abundance, and,
surprisingly, antagonised neurodifferentiation induced by
PCF11 depletion (Fig. 6e, f). Further, in line with our preceding
observations demonstrating a functional role in WNT signalling
(Fig. 4b, c, Supplementary Figure 6a) these manipulations are
associated with corresponding alterations of the WNT pathway
(Fig. 6e, reflected by the regulation of TCF7). Thus, selectively
shifting the relative proportion of the long vs. the short GNB1
transcript isoform towards a ‘PCF11-high-level’ phenotype (that
is a more prevalent short isoform) reverts a neurodifferentiation
programme induced by PCF11-downmodulation. This directly
corroborates the functional importance of PCF11-directed APA
regulation, in which alterations of GNB1 transcript isoforms
appear to play a central and causative role. It provides a
mechanistic explanation for the observed clinical phenotypes,
showing a particularly poor patient outcome under conditions of
high-level PCF11 expression, predominant expression of short
TREND isoforms of a neurodifferentiation operon (including
AES, IGF1R and GNB1), followed by downstream aberrations of
WNT signalling and defective terminal differentiation of
neuroblastomas.
PCF11-directed TREND signatures are potent biomarkers. To
investigate the clinical implications of these findings, we finally
explored whether the functional importance of PCF11-directed
APA for neurodifferentiation is more generally reflected in
patient outcome, and whether perturbed TREND signatures
might thus have prognostic potential. Applying receiver operating
characteristic (ROC) curve analysis reflecting the relative abun-
dance of PCF11-regulated long and short transcript isoforms, we
identify that individual PCF11-mediated TREND signatures
(including GNB1) appear to discriminate high- and low-risk
neuroblastomas as well as death surprisingly better than common
clinically used predictive markers of tumour progression (e.g.
MYCN amplification; Fig. 7a, Supplementary Table 6, for p-value
comparison between predictive power of established risk marker
expression and combined TREND patterns see Supplementary
Table 7, Cox modelling Supplementary Figure 7d). In contrast,
the mere RNA abundance of these APA-affected candidates fails
to be predictive and shows a comparatively poor prognostic
power (Fig. 7b). Of note, this highly prognostic module also
includes GNG2, a functionally important dimerisation partner of
GNB1.
Altogether, these data illustrate the functional role and
prognostic importance of perturbations at the mRNA 3′ end of
an APA-affected set of transcripts with a role in neurodifferentia-
tion in neuroblastoma. They establish PCF11 as a critical
regulator of neurogenesis with aberrant PCF11 causing pervasive
(de)regulation of APA bearing detrimental consequences for
normal neurodifferentiation and a functional role in neuroblas-
toma tumorigenesis. Intriguingly, alterations of the PCF11-GNB1
axis with downstream perturbations of WNT signalling seem to
play a central role in this process.
Discussion
Diversification at the transcriptome 3′ end is a widespread and
evolutionarily conserved gene regulatory mechanism. Although
TREND has been associated with differentiation and dediffer-
entiation processes16,17, the underlying mechanisms and func-
tional consequences are still poorly defined5,19. Here we identify
massive alterations of the transcriptome 3′end architecture in
neuroblastoma. This tumour entity is characterised by a general
paucity of somatic mutations2 and a comparatively high, yet
mechanistically enigmatic, incidence of spontaneous tumour
regression45. By applying a global RNAi screening of a rationally
chosen set of factors controlling various facets of RNA metabo-
lism, we delineate the dynamic landscape of TREND in neuro-
blastoma. While depletion of most TREND regulators leads to an
even distribution of transcript isoform shortening and lengthen-
ing, the depletion of CFIm and CFIIm complex components
belonging to the pre-mRNA 3′end processing machinery results
in an almost uniform shortening or lengthening phenotype,
respectively (TREND-DB: http://shiny.imbei.uni-mainz.de:3838/
trend-db). This suggests an important regulatory function of
these TREND regulators in global transcriptome 3′end organi-
sation (with individual factors regulating 1000 and more genes,
Supplementary Table 2). Interestingly both, TREND regulators
and TREND-affected genes, share high phylogenetic conserva-
tion, and numerous components of the canonical 3′end proces-
sing machinery control RNA 3′end diversification of genes with
an important role in tumorigenesis.
Mechanistically, PCF11, together with CLP1 (both of which
form a functional heterodimer), constitute the only TREND
Fig. 4 PCF11-directed APA regulation converges on WNT signalling and modulates cell cycle progression, proliferation, apoptosis and neuronal
differentiation. a Effect of PCF11-mediated APA regulation on protein expression of APA-affected targets (red) and downstream signalling pathways
compared to a control knockdown. b Protein-protein interaction network of validated APA-affected candidates (red) impinging on WNT signalling (i.e.
CTNNB1, bold; String-DB). This corresponds to the predicted function of the entire cohort of APA-affected genes with a role in neurodifferentiation
(compare Supplementary Figure 6a). c shRNA-mediated depletion of PCF11 induced by IPTG (see Methods section) inhibits canonical WNT signalling in
reporter assays (compare bar 2 with 6). WNT antagonists BML286 and NSC668039, and WNT5A (a non-canonical WNT-ligand) confirm specificity of
pathway activation and functionality of the beta-catenin TCF/LEF-driven gene-reporter construct, respectively (for PCF11-APA-directed regulation of WNT
signalling and its specific control via different transcript isoforms encoding GNB1 see endogenous TCF7 expression in Fig. 6e). PCF11 depletion results in d
cell cycle retardation, e reduced proliferation, f increased apoptosis (ELISA-DNA fragmentation assay; n= 3; a loss-of-apoptosis phenotype upon PCF11
overexpression is shown in Supplementary Figure 6b) and g triggers neuroblastoma differentiation morphologically and molecularly (for PCF11 depletion-
induced neuronal differentiation of neuroblastic CHP-134 cells see Supplementary Figure 6c). Error bars in a–g show mean ± s.e.m. of at least three
independent experiments, one-sided t-test p-value; *p < 0.05, **p < 0.01, ***p < 0.001; FC fold change, cells are stained with an antibody directed against
TUBB3 (red), nuclei are stained with DAPI (blue)
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regulators whose downregulation predominantly results in APA
far downstream (Fig. 2b, c, Supplementary Figure 2d)49. This is
consistent with the role of PCF11 in modulating Pol II pro-
cessivity and transcription termination50, and thereby provides a
possible mechanistic explanation for the widespread lengthening
of 3′ UTRs in the mammalian brain39. Neuronal PCF11 expres-
sion drops around birth and during neuronal differentiation, but
appears to be high in neuroblastomas and, interestingly, other
paediatric cancer entities with embryonic origin (Fig. 7c). Thus, it
is tempting to speculate that sustained (postnatal) PCF11
expression may drive highly proliferative embryonic programmes
by arresting cells in an undifferentiated state. This could also
explain the high frequency of microscopic neuroblastic lesions in
fetuses51 or young infants52 compared to older ages, although
future studies are needed to dissect the role of PCF11 for
embryonic development in further detail.
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Fig. 6 Lengthening of the Gβγ-complex component GNB1 transcript is a central checkpoint in PCF11-TREND-mediated neuroblastoma differentiation.
a PCF11 is significantly lower in low-risk compared to high-risk neuroblastoma patients (p= 0.005172; two-sided t-test; GSE4971044, ordered according to
PCF11 expression; 10th percentile). b Low PCF11 in stage 4S neuroblastoma patients (compare Fig. 5g) is associated with pervasive TREND-lengthening
(Supplementary Table 5; stage 4S, n= 48; stage 4, n= 65) including AES, IGF1R and GNB1. c GNB1 transcript lengthening correlates with a superior
outcome in neuroblastoma patients (two-sided t-test). d GNB1 protein abundance (recorded by luciferase reporter assay) is determined by the GNB1 3′
UTR transcript isoform (middle; scheme of GNB1 3′ UTR luciferase reporter is shown in top). ‘Full’ and ‘Short’ denote 3′ UTR luciferase reporter constructs
harbouring the (full-length) GNB1 3′ UTR processed at the distal or proximal polyadenylation signal (compare IGV track on the bottom before and after
PCF11 depletion, for details see also legend to Fig. 2a). ‘Long’ indicates a construct with a 3′ UTR corresponding to sequences unique for the long transcript
isoform (bar diagrams represent mean ± s.e.m. and a one-sided t-test p-value). e Depletion of the long GNB1 transcript isoform (siGNB1-L) in a low- or
high-level PCF11 background (siRNA target sites highlighted in IGV tracks on top) results in reciprocal GNB1 mRNA isoform expression (middle panel) and
protein output (lower panel) and counteracts a PCF11-KD-driven inhibition of WNT signalling (TCF7, compare Fig. 4c) and differentiation of neuroblastoma
molecularly (TUBB3) and f phenotypically (cells are stained with an antibody directed against TUBB3 (red), nuclei are stained with DAPI (blue), scale bar
= 100 µm). For box plots, centre line depicts median, hinges show 25th and 75th percentile, whiskers depict interquartile range (IQR= 1.5). *p < 0.05,
**p < 0.01, ***p < 0.001
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This study puts PCF11 at centre stage as it affects TREND in
neuroblastoma most quantitatively and in a dominant manner.
PCF11-directed APA controls a neurodifferentiation RNA
operon. Downregulation of PCF11 induces neuronal differentia-
tion of BE(2)-C and CHP-134 neuroblastomas and murine neu-
ronal precursors, conversely forced overexpression halts
neurodifferentiation. This suggests a more general critical func-
tion of PCF11 and the resulting downstream organisation of
TREND in this process. In line with these findings, we identify
(de)regulated APA as a pivotal mechanism linking aberrant
PCF11 expression with neuroblastoma formation and prognosis;
high-level PCF11 specifies a poor prognosis (p= 0.00275) and a
low likelihood of spontaneous tumour regression (p < 0.001).
Our data suggest the WNT signalling pathway to represent an
important convergence point for neurodifferentiation, which,
when deregulated through aberrations of APA, contributes to
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Fig. 7 PCF11-derived TREND signatures predict superior patient outcome. a Predictive potential of TREND signatures (red) compared to common stratifiers
in neuroblastoma (blue, Supplementary Table 6) with (n= 493, left) or without (n= 401, right) MYCN amplification (p-values, Supplementary Table 7,
Cox-modelling Supplementary Figure 7e). Receiver-operating characteristic (ROC) curve reflecting the ratio of short-to-long isoform abundance of PCF11-
TREND-affected genes (with AUC > 0.7) for predicting death (upper panels) or association with high risk (lower panels). Red line depicts predictive power
of a combined TREND pattern (multifactor ROC) compared to ROC based on expression of established risk markers (MYCN and ALK82; grey lines reflect
ROC for 3′end isoform patterns of individual TREND-affected genes, GSE4971044; Supplementary Table 6). b ROC curves reflecting TREND alterations
(red) of genes belonging to the neurodifferentiation TREND operon highlight the predictive power of deregulated TREND signatures compared to the poor
sensitivity and specificity of the mere mRNA abundance (orange; n= 493, raw data same as for a; TREND isoforms and mRNA abundance of RBM17, ELP2
and AKT2 (lower row) serve as control confirming absence of analytical bias in favour of TREND). c High-level PCF11 mRNA expression in other paediatric
malignancies with embryonic origin including medulloblastomas (GSE35493), Ewing sarcomas (GSE17679) and primitive neuroectodermal tumours
(PNET, GSE17679) compared to respective controls (red; expression data obtained from R2 (http://r2.amc.nl)). For box plots, centre line depicts median,
hinges show 25th and 75th percentile, whiskers depict interquartile range (IQR= 1.5), two-sided t-test. **p < 0.01, ***p < 0.001. d Integrated model for
PCF11-dependent TREND regulation in neuroblastoma governing neurodifferentiation (details see text). Briefly, (1) postnatal downregulation of PCF11 is
believed to (2) reduce efficiency of transcription termination20,21, facilitating (3) alternative polyadenylation (APA) at distal (3′ located) polyadenylation
(pA) signals (red), affecting TREND of >900 RNAs (4). This includes a neurodifferentiation TREND operon (Fig. 3b), shaping (5) WNT signalling to induce
neurodifferentiation. Conversely, sustained (postnatal) high-level PCF11 expression arrests neuronal precursors in an undifferentiated state by promoting
polyadenylation at proximal pA (blue), thereby controlling protein output of the neurodifferentiation TREND operon. Transcript isoform regulation of GNB1,
a modulator of various transmembrane signalling pathways48 with a role in development63, malignant transformation64 and neurodevelopmental
disorders65 is prerequisite for PCF11-dependent regulation of neurodifferentiation. Notably, GNB1 was previously identified as marker for spontaneous
neuroblastoma regression41
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neuroblastoma genesis. Interestingly, aberrant WNT signalling
has been implicated in neuroblastoma formation53–59. Among
APA-affected transcripts, the Gβγ-complex component GNB1
appears to have a decisive function in this process. In addition to
its function in heterotrimeric G-protein signalling with a role in
pathways essential to development, it modulates WNT signalling
(Figs. 4c and 6e)60–62, and selective depletion of its long transcript
isoform abolishes an otherwise dominantly driven neurodiffer-
entiation phenotype induced by PCF11 downregulation. Notably,
GNB1 was previously identified as a marker for spontaneous
neuroblastoma regression41. GNB1 is also affected by APA in a
PCF11-like manner upon depletion of BARD1 (see TREND-DB),
one of the few factors in which germline mutations have been
linked to neuroblastoma formation13. Apart from its global role
in development63, constitutive activation of GNB1 has been
shown to promote malignant transformation64 and neurodeve-
lopmental disorders65. Thus, together with IGF1R66, AES67,68 and
EIF2S1 (at least) four members of the neurodifferentiation APA-
RNA operon converge on WNT signalling (Fig. 4b, c, Supple-
mentary Figure 6a) with important functional implications
(Figs. 4c–g, 5a–e and 6e, f). This reflects the critical role of WNT
in directing cell fates during embryogenesis and in a variety of
human cancers69. Aberrant PCF11, therefore, could functionally
‘compensate’ for lack of germline mutations in WNT signalling
molecules of (hitherto unidentified) WNT-driven pathologies.
This could account for neuroblastomas, and may also explain
why many cancers without mutations in the WNT pathway still
rely on aberrant WNT signalling for proliferation or survival70,
offering an interesting and to be further explored possible
mechanism for the effect of APA on neurodifferentiation and
beyond.
Post-transcriptional perturbances are increasingly recognised
to play a critical role in tumorigenesis, including childhood
neuroblastomas71. The 3′ UTR aberrations identified here in
neuroblastoma can be easily dismissed as irrelevant and/or
remain undetected as they affect non-coding elements. Our data
highlight the functional relevance of these non-coding elements
in driving most devastating processes. They also illustrate that
functionally most relevant alterations at the transcriptome 3′ end
are prone to escape conventional gene expression profiling19. Our
observations suggest that TREND signatures could represent
powerful biomarkers for neuroblastoma risk stratification and
may have the potential to explain previously counterintuitive
(clinical and basic research) findings. However, comprehensive
studies based on larger and independent patient cohorts are
required to further illuminate the clinical implications. In addi-
tion, the identification and analysis of aberrations of the tran-
scriptome 3′ end is likely to have far-reaching implications for the
elucidation of disease mechanisms beyond neuroblastoma for-
mation11 and the quest for novel tailored therapies72.
Methods
siRNA library. A custom siGENOME library was purchased at Dharmacon (GE
Healthcare) and consisted of siRNA smartpools to deplete targets listed in Sup-
plementary Table 2.
Mammalian cell lines. Neuroblastoma cell lines (CHP-134, LAN-6 and SH-SY5Y)
were purchased from Leibniz Institute DSMZ—German Collection of Micro-
organisms and Cell Culture. The BE(2)-C cell line was a generous gift from Prof.
Olaf Witt (DKFZ, Heidelberg). All cells were tested negative for mycoplasma, and
propagated in monolayer culture in Dulbecco’s modified Eagle’s medium medium
with 10% foetal bovine serum (10–30 passages). BE(2)-C were differentiated using
5 µM ATRA.
Transfection of mammalian cell culture. Cells were plated (60–70% confluence)
12 h prior to the transfection procedure. A master mix for transfection included
RotiFect RNAi Lipo (Roth, 2 µl/1 ml of total transfection volume), siRNA (50 nM
final) or plasmid (0.5 µg/ml final) mixed in OptiMEM (ThermoFisher Scientific)
in 20% of final volume according to the manufacturer’s instruction. Cells were
assayed 48–72 h after transfection.
Generation of stable cell lines. To generate clones with IPTG-inducible expres-
sion of specific shRNA directed against PCF11 or firefly luciferase (as negative
control respectively), BE(2)-C and CHP-134 were transfected with pLKO-puro-
IPTG-3xLacO constructs (Sigma-Aldrich). Antibiotic selection was performed with
3 µg/ml of puromycin (ThermoFisher Scientific).
Stable cell lines overexpressing PCF11 were generated by transfection of the
wild-type BE(2)-C and CHP-134 neuroblastoma. For stable overexpression, a pCI-
neo plasmid containing a full-length PCF11 coding sequence with N-terminal Flag
peptide was transfected. An empty pCI-neo vector was used to generate a control
cell line. For selection of clones with stable integration, Geneticin® G-418
(ThermoFisher Scientific) treatment was initiated 48 h after transfection (1 mg/
ml) and carried out for the following 10 days. Individual clones were then
propagated and tested for target protein overexpression or depletion using western
blotting73.
Constructs. For WNT-luciferase reporter assays, the plasmid M50 Super 8x
TOPFlash (#12456, AddGene) was used. It contains TCF/LEF sites for beta-
catenin-mediated transcriptional activation upstream of a firefly luciferase gene.
Co-transfection was performed with pRL-TK (#E2241, Promega), and firefly
luciferase luminescence was normalised to renilla luciferase.
For GNB1 3′ UTR reporter assays, the plasmid pmirGLO (#E1330) was used.
Complete or parts of GNB1 gene 3′ UTR were cloned downstream of the Firefly
luciferase open reading frame using the following primers:
FF_short: ATACAAGCTAGCCGCCAGTAGCATGTGGATGC;
Rev_short: GATGGCCTCGAGTCAAGTTTACCTTCTGGTTA;
FF_long: ATACAAGCTAGCGTAAACTTGAGTGTAATTGT;
Rev_long: GATGGCCTCGAGGTCCCTCATGTCAAACTGCT
A set of constructs containing specific shRNA sequences to target human
PCF11 mRNA was designed by Sigma-Aldrich based on pLKO-puro-IPTG-
3xLacO backbone. Target sequences for PCF11 depletion were:
ATCGAAATCGAAATCGAAATC, AGTAGCCTCCCACTGATTAAA,
AGATCCTGCTTGGCCTATTAA (was used throughout all functional
experiments), CAATCAGACTGGTCCATATAA and
TTTGCCATCGGTCTTATC.
For overexpression studies, the coding sequence of human PCF11 protein was
cloned into pCI-neo vector backbone (#E1841, Promega). The cDNA was cloned
by fusion of two fragments. Amplicons were synthesised using the two following
primer pairs for the 5′ and 3′ fragment respectively:
FF1: AAGCCACCGCTCGAGTCAGAGCAGACGCCGGCC,
Rev1: AAGCCACCGCTCGAGATGTCAGAGCAGACGCCGGCC;
FF2: GTGTGCGAGAAGAGCAGAGA,
Rev2: CGGGTCGACTCTAGATTAAACTGACTCGACTGTGTCAT
Both parts were inserted into pCI-neo with a Flag peptide-coding sequence in
the multiple-cloning site. Ligation was performed using the InFusion cloning kit
(Clontech® Laboratories) according to the manufacturer’s instructions.
Northern blotting. Total RNA was extracted from cells using PeqGold TriFast
(VWR). Northern blotting analysis (in an agarose gel system) was performed as
described previously73. For higher resolution (in the range of 200–2000 nt) poly-
acrylamide gel systems were used. Specifically, total RNA was deadenylated in
presence of 200 pmol of oligo-(dT)25 and 5 units of RNase H. Purified RNA (1–3
µg) was heat-denatured in 50% formamide in TAE and separated in a poly-
acrylamide gel consisting of 3.5% polymerised acrylamide-methylenebisacrylamide
mix (37.5:1), 7 M urea. Electrophoresis was performed in TAE buffer for 4 h at 140
V. RNA was transferred to a nylon membrane (ThermoFisher Scientific) by semi-
dry electroblotting. Membranes were ultraviolet cross-linked and hybridised with
specific probes in analogy to the standard procedure73.
Non-radioactive DNA probe synthesis and detection. For specific DNA probe
synthesis (for Northern blotting), RNA was reversely transcribed. PCR amplicons
(of about 450–550 base pairs long) were generated using OneTaq Master Mix (New
England BioLabs). Purified PCR products (1–3 ng) were used in the next round of
asymmetric PCR (reverse to forward primers ratio 100:1) to generate biotin-
labelled probes (50 PCR cycles). Probes were purified by extraction from agarose
gels by using NucleoSpin® Gel and PCR Clean-up kit (Macherey-Nagel). For
hybridisation, 50–100 ng of probe was used in 5 mL of Church buffer in analogy to
procedures described previously73. For the detection of biotinylated probes,
membranes were washed and blocked for 1 h in solution containing 1x TBS, 0.5%
SDS and 0.1% of Aurora™ Blocking Reagent (#04821548, MP Biomedicals).
Streptavidin−Peroxidase Polymer (#S2438, Sigma-Aldrich) was used next (diluted
1/7000) for 1 h, following 3 cycles of 10 min washing (with 1x TBS, 0.5% SDS).
Signal detection was carried out by using ECL Select Western Blotting Detection
Reagent (GE Healthcare). Blots were scanned using ChemiDoc™ MP System (Bio-
Rad) and bands were quantified (Image Lab™ software; Bio-Rad).
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Western blotting. Protein lysates were generated as described previously73 and
separated using Criterion™ TGX™ Stain-Free™ gel (Bio-Rad Laboratories) followed
by transfer onto nitrocellulose membrane (GE Healthcare). Equal sample loading
was assayed by in-gel fluorescent detection or Ponceau S staining of the membrane.
Membranes were blocked with TBS buffer containing 5% milk for 1 h and probed
with specific antibodies. All antibodies used were purchased at Bethyl Laboratories
with exception for: IGF1R, EIF3AK, pEIF3AK, ATF4, GNB1 and MYCN (Santa
Cruz Biotechnology); AKT and pAKT (Cell signalling Technology); pEIF2S1
(Abcam); TUBB3 (BioLegend); AES (Novus Biologicals). Blots were scanned using
ChemiDoc™ MP System (Bio-Rad) and bands were quantified Image Lab™ software
(Bio-Rad). Uncropped blots of the main figures are shown in Supplementary
Figure 8.
Neuroblastoma TREND annotation assembly. 3′READS was carried out as
previously described15. Briefly, total RNA obtained from differentiated and
undifferentiated neuroblastoma cell line (BE(2)-C) was subjected to 1 round of
poly(A) selection using oligo(dT) beads (NEB), followed by fragmentation on-bead
with RNase III (NEB). Poly(A)-containing RNA fragments were isolated using the
MyOne streptavidin C1 beads (Invitrogen) coated with a 5′ biotinylated chimeric
dT45 U5 oligo (Sigma), followed by washing and elution through digestion of the
poly(A) tail with RNase H. The part of the poly(A)-tail annealed to the U residues
of the oligo was refractory to digestion and was thus used as evidence of the poly
(A) tail. Eluted RNA fragments were purified by phenol-chloroform extraction and
ethanol precipitation, followed by sequential ligation to a 5′-adenylated 3′-adapter
(5′-rApp/NNNNGATCGTCGGACTGTAGAACTCTGAAC/3ddC) with the
truncated T4 RNA ligase II (NEB) and to a 5′ adapter (5′-GUUCAGAGUUCUA
CAGUCCGACGAUC) by T4 RNA ligase I (NEB). The resultant RNA was reverse-
transcribed with Superscript III (Invitrogen), followed by 12 cycles of PCR
amplification with Phusion high fidelity polymerase (NEB). cDNA libraries were
sequenced on an Illumina HiSeq 2500.
Filtered poly(A) site-supporting (PASS) reads were used to construct peaks
using the Cufflinks software. Obtained peaks were associated with the UCSC
assembly of human genes based on the peaks position using the closest-features
command of BEDOPS toolkit. PASS mapped within the 5000 nucleotide region
downstream of the annotated gene were considered as novel 3′ UTR isoforms. This
annotation was used to exclude TRENDseq reads originating from internal priming
on the genome encoded adenosine-rich regions. For mouse annotation of true poly
(A) sites, data (PMID 24072873) were used with settings identical for human
neuroblastoma annotation.
Nucleic acid quality assurance. RNA integrity was assayed with Agilent RNA
6000 Nano Kit (Agilent Technologies) according to the manufacturer’s instruc-
tions74, and a threshold of minimal RNA integrity number of 9.5 was applied for
total RNA. Homogeneity and size of DNA libraries for Illumina sequencing were
analysed using Agilent High Sensitivity DNA Kit (Agilent Technologies) following
the manufacturer’s instructions. Qubit® 2.0 Fluorometer in combination with
dsDNA HS Assay Kit (ThermoFisher Scientific) was used to assay cDNA library
concentration.
TRENDseq: library preparation and sequencing. Total RNA (100 ng) was
reverse-transcribed in presence of oligonucleotide (RT) primer containing T7
promoter, Illumina 5′ adapter, individual in-lane barcode and an anchored oligo-
dT stretch, as described previously75. For the cDNA and aRNA synthesis Messa-
geAmp II aRNA Amplification Kit (ThermoFisher Scientific) was used according to
the manufacturer’s recommendations with modifications. Specifically, for the first
and second cDNA strand synthesis for each individual RNA input sample 1/10 of
full reaction size was used. Up to 25 samples were pooled after second cDNA
strand synthesis reaction. In vitro transcription (aRNA synthesis) was performed in
40 µl reaction format according to the manufacturer’s protocol with 14 h of
incubation at 37 °C. Purified aRNA was sheared using Covaris M220 Focused-
Ultrasonicator™ (Peak incident power 50 Watt, Duty Factor 20% and 200 Cycles
per Burst (cbp) for 420 s at 7 °C) and size-selected on the 6% PAGE in denaturing
conditions (7 M urea). The gel region corresponding to 100 nucleotides was
excised, and RNA was eluted from gel by 2 min incubation in 50–100 µl of buffer
containing 100 mM Tris-HCl (pH 8.0), 500 mM NaCl and 1% SDS at room
temperature. Size-selected RNA was purified using miRNeasy Kit (Qiagen).
Illumina platform compatible cDNA library was synthesised as described
previously75 with a number of PCR cycles reduced down to 9. Each pooled library
(up to 25 samples) was labelled with Illumina indexing barcode and up to three
libraries were pooled together adding up to 75 samples per sequencing run. The
libraries were sequenced on the Illumina HiSeq or NextSeq platform with addition
of 30% PhiX Sequencing control (Illumina) in the paired-end setup. Read 1 (9 nt)
sequenced individual sample in-lane barcode (introduced in the first reverse
transcription-step) and read 2 (50 nt) sequenced the RNA insert to be mapped to
the genome (Fig. 2a). Illumina indexes were sequenced as a dedicated read.
TRENDseq: bioinformatical analysis. Raw sequencing data (fastq format) were
demultiplexed using in-lane RT primer barcode with the average per base quality
score above 20, followed by A- and T-stretches trimming as described previously75.
Resulting sequences with average length of 25–35 nucleotides were mapped to
human hg38 genome using bowtie2 aligner. Mapped reads were filtered from
internal priming events using the assembly of TREND annotation (see above). The
number of reads associated with each TREND isoform was calculated using HTSeq
(htseq-count command, intersection-strict option). Number of reads aligned to
each site reflect expression of an individual 3′end isoform.
For statistical analysis, the expression level of each transcript isoform was
examined by Fisher’s exact test in comparison to the respective other alternative
3′end isoform(s) expressed by the same gene. Contingency table included the
number of reads of the tested isoform and total amount of reads of all the other
isoforms of the gene (for the knockdown and control samples, respectively).
Obtained p-values were adjusted using the Benjamini-Hochberg method, and
adjusted p-value ≤ 0.05 filter was applied. To calculate fold-regulation per isoform,
total amount of reads for each gene was normalised to 100%, and percentage of
individual isoform in the knockdown sample was divided by the percentage of the
same isoform in the control.
The most 3′end position and fold change of regulated transcript isoforms
(Fig. 2b and Supplementary Figure 3c) was calculated relative to the ‘Zero-isoform’,
which is defined as the longest significantly affected (BH-adjusted p ≤ 0.05) and
annotated transcript isoform expressed by the respective gene. To describe the
overall tendency of a given gene to express shortened (or lengthened, respectively)
transcript isoforms, a proxy of two most significantly affected isoforms was applied
(Supplementary Figure 2c, Fig. 3b and Supplementary Figure 3b, d). The
shortening index was calculated as the fold-regulation of the shorter isoform
normalised to the fold-regulation of the longer isoform of the same gene (a positive
log2 shortening index represents a higher abundance of the shorter transcript
isoform upon depletion of the respective TREND regulator, and vice versa). GO
analysis was performed using DAVID functional annotation tool (version 6.7). The
network analysis (Supplementary Figure 3b) was built according to the
Fruchterman-Reingold algorithm based on force directed nodes placement,
wherein the distance between the nodes reflects the total number of affected genes
and significance of antagonistic or synergistic action by repulsion or attraction,
respectively.
Programming and packages. TRENDseq data analysis and visualisation was
performed in the R environment76 (https://www.R-project.org/). Packages used:
gplots, igraph, ggplot2, pROC, limma, survival.
Immunofluorescent micrographs. Cells were plated onto sterile microscopy
coverslips and propagated under the experimental conditions (detailed above).
Fixation was performed for 10 min in phosphate-buffered saline (PBS) solution
containing 4% paraformaldehyde and 10 mM NH4Cl. Cells were permeabilised
with 0.2% Triton X-100 in PBS at room temperature for 10 min. Cells were blocked
with 2.5% Normal Horse Serum Blocking Solution (Vector Laboratories) for 1 h
and stained with a primary antibody directed against TUBB3 in PBS solution
containing 1% bovine serum albumin (BSA) and 0.05% Triton X-100. After
staining with Cy3-labelled secondary antibody (anti-rabbit) samples were mount
onto microscope slides with Vectashield Antifade Mounting Medium containing
the 4′,6-diamidino-2-phenylindole (DAPI) stain (Vector Laboratories). Image
analysis was performed using ImageJ.
Apoptosis assay. Apoptosis measurements were performed using the Cellular
DNA Fragmentation ELISA kit (Sigma-Aldrich). BE(2)-C cells were plated in black
96-well plates with transparent bottom in duplicates (5000 cells/well). A unit of 1
mM IPTG was added to the cells to induce PCF11 depletion (see above). Seventy-
two hours after plating, cells were labelled with 10 µM bromodeoxyuridine (BrdU)
for 24 h. After BrdU withdrawal, cells were kept in culture for another 48 h. For cell
lines with stable PCF11 overexpression, 3 µg/ml of puromycin or 1 µM lometrexol
(Sigma-Aldrich) was applied to trigger apoptotic response for the same period after
BrdU withdrawal. After 48 h and prior to the harvesting procedure, cells were
labelled with NucBlue® Live ReadyProbes® Reagent (ThermoFisher Scientific) for
30 min (2 droplets of reagent per 1 ml of media). After washing with PBS, cells
were imaged with fluorescence microplate reader (Fluoroskan Ascent FL, Ther-
moFisher Scientific), and the signal at the wavelength ~461 nm was used as a
measure of cell number in the well (as normalisation control). Thereafter, the
ELISA procedure was performed according to the manufacturer’s instructions
(Cellular DNA Fragmentation ELISA kit protocol). The colorimetric signal was
normalised to the cell number in each well.
Cell cycle analysis. PCF11 knockdown in BE(2)-C cells was performed by siRNA
transfection as described above. Forty-eight hours after transfection, cells were
synchronised with 2 mM hydroxyurea (HU) for 16 h. Cells were harvested at 0, 3,
6, 9 and 12 h after HU withdrawal. Cells were treated with 30–50 µg/ml of pro-
pidium iodide (ThermoFisher Scientific) solution in 0.1% Triton X-100 in PBS in
presence of 2 mg of DNase-free RNase A (ThermoFisher Scientific). After staining
for 15 min at 37 °C, the fluorescent signal was measured with a LSR II Flow
Cytometer (BD Biosciences) using a 670 nm long-pass filter. Cell doublet dis-
crimination was performed using FSC-H/FSC-A, SSC-H/SSC-A and PI-H/PI-A
gates.
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Proliferation assay. Cells were plated in black 96-well plates with clear bottom in
10 replicates (3000 cells/well). PCF11 knockdown was performed by addition of 1
mM IPTG to the culture medium (see above). After 48 h of incubation, two
replicates were stained for 30 min with NucBlue® Live ReadyProbes® Reagent
(ThermoFisher Scientific) according to the manufacturer’s recommendations. Cells
were washed in PBS, and the signal was measured with a fluorescence microplate
reader (Fluoroskan Ascent FL, ThermoFisher Scientific, ~460 nm wavelength). The
procedure was repeated over 5 days with two fresh replicates to assay proliferation
kinetics.
Colony formation assay. For colony formation assays, 200 BE(2)-C cells (see
above) were plated into each well of a six-well plate for 10 days without and with
addition of IPTG. Thereafter, the cells were washed and fixed, and colonies were
stained with 0.5% crystal violet for 10 min at room temperature.
Matrigel invasion assay. To assess the invasive properties upon PCF11 depletion,
80,000 BE(2)-C cells (see above) were seeded into the insert of a growth factor
reduced 24-well MatrigelTM invasion chamber assay plate (BD BioCoatTM) without
and with addition of IPTG (in 0.5 ml serum-free media); the inserts were trans-
ferred into wells containing 0.75 ml culture medium with 10% fetal calf serum with
and without IPTG. After 72 h, non-invading cells were removed from the upper
surface of the membrane with a cotton swab, and invading cells were fixed and
stained with Diff-Quick® (Medion Diagnostics) and quantified by counting invaded
cells in four independent areas in pentaplicates. All experiments were performed in
accordance with the manufacturer’s protocols.
Mouse tumour xenotransplantation. Female athymic nude mice (Crl:NU(NCr)-
Foxn1nu, Charles River) were used to assess tumour progression of BE(2)-C cells in
response to the PCF11 expression status. To that end, 12.5 × 106 cells each in 0.2 ml
PBS were subcutaneously injected into the right/left flank of 30 nude mice (aged
6 weeks, weighting ~20–25 g). For PCF11 depletion, half of the animals were
randomly assigned to a cohort (on day 3 after tumour transplantation), which
received IPTG injections (1.95 M, Roth, Germany) every second or third day
(injection of PBS served as negative control), and tumour dimensions were mea-
sured with callipers every 2 or 3 days. Tumour volume was calculated by modified
ellipsoid formula (½ × (length × width2)); mice were sacrificed after a follow-up of
~20 days after tumour cell injection and tumours were removed and weighted. All
animal experiments were approved by local authorities (Rhineland-Palatinate), and
animals’ care was in accordance with institutional guidelines.
Luciferase reporter assay. For the WNT reporter assays wild-type BE(2)-C or
clones with inducible shRNAs directed against PCF11 (see above) were plated 12 h
prior to the procedure in 24-well plates with or without 1 mM IPTG. Transfection
with 1.6 µg of TOPFlash plasmid and 0.4 µg of pRL-TK (control) was performed in
antibiotic-free medium. Modulators of WNT and IGF1R pathways were added in
serum-free OptiMEM medium 48 h after reporter transfection. WNT pathway
activation was induced by addition of recombinant WNT-3a (canonical) or WNT-
5a (non-canonical WNT-ligand; each 250 ng/ml, R&D Systems®, diluted in 0.1%
BSA-PBS). WNT pathway inhibition was carried out by addition of 0.2 mM BML-
286 (Enzo Life Sciences) or 1 mM NSC668036 (Sigma-Aldrich). IGF1R was
inhibited by adding 25–50 µM Tyrphostin AG1024 (Enzo Life Sciences). Dimethyl
sulphoxide was used as a solvent control for inhibitors of the WNT and IGF1R
pathways.
For monitoring WNT activity, luciferase assays were carried out 24 h after
compound addition (see above). Cells were lysed in 12-well plates with Passive
Lysis buffer (Promega) for 15 min at room temperature. Firefly and Renilla
luciferase luminescence was assayed in reactions with Bright-Glo™ reagent
(Promega) and coelenterazine (Promega), respectively. Firefly luciferase was used
as a read-out for WNT signalling pathway activation and normalised to the
luminescence of Renilla luciferase (vector delivery control).
For analysis of the effect of GNB1 3′ UTR isoforms on luciferase expression,
pmirGLO-constructs were transfected into wild-type BE(2)-C in 12-well plates.
Luciferase activity was assayed 24 h later as described above.
Inducible PCF11-RNAi mouse model. For reversible depletion of PCF11, an
inducible knockdown allele of the PCF11 gene was generated via targeted trans-
genesis of a doxycycline-inducible shRNA cassette into the ROSA26 locus (Gt
(ROSA)26Sor)77. Briefly, to that end a recombination-mediated cassette exchange
vector harbouring an inducible H1 promoter (H1tetO)-driven shRNA cassette
along with a genetic element for the constitutive expression of the codon-optimised
tetracycline repressor protein (iTetR), and a neomycin resistance cassette was
transfected into C57BL/6 ES cell line equipped with RMCE docking sites in the
ROSA26 locus. Recombinant clones were isolated using neomycin resistance
selection and positive clones harbouring six different shRNAs targeting PCF11
were pretested for knockdown potency in ES cells (by qPCR analysis with the
following gene expression assay IDs (ThermoFischer); Pcf11: Mm01324032_m1
(exon 1–2) and Mm01324024_m1 (exon 9–10); housekeeper: 4352339E). The clone
with highest knockdown efficiency was used for the generation of the mouse line.
All animal experiments were approved by local authorities, and animals’ care was
in accordance with institutional guidelines.
In vitro differentiation of murine neurons. To assay the effect of PCF11 on
neuronal differentiation, primary murine neurons were harvested from PCF11 KD
(animals) and litter control embryos (E18) by using a neuronal tissue dissociation
kit (Miltenyi Biotec). Thereafter, 5000 cells were seeded onto coverslips with pri-
mary murine astrocytes as feeder cell (plated 24 h before) in 24-well plates in
duplicates. The effect of PCF11 depletion on neurodifferentiation was assessed
4 days after addition of doxycycline (1 µM) to neuronal precursors obtained from
PCF11 KD and litter control embryos. To that end, cells were fixed, permeabilised
and stained with a primary- (TUBB3) and a Cy3-labelled secondary antibody (as
above). Finally, the samples were mount onto microscope slides with Vectashield
Antifade Mounting Medium (Vectashield) and the extent of neuronal differ-
entiation was calculated by applying the Neurite Tracer plugin of ImageJ.
Extraction of TREND signatures from microarray data. In order to assay the
relative proportion of transcript isoforms with shortened or elongated 3′ ends in
the GEO GSE49710 data set44 we selected probes of the relevant microarray
platform that could distinguish different TREND isoforms of the same gene. To do
so sequences of all probes of Agilent-020382 Human Custom Microarray 44k were
mapped to the human genome (version GRCh38/hg38) using STAR78. Resulting
mappings were overlapped exclusively with tandem sites obtained from the
TREND annotation to associate probes with TREND isoforms detected in our
experimental setup. Raw microarray data were downloaded from GEO
(GSE4971044), background-corrected and quantile-normalised using bioconductor
limma package79. Only genes with probes that could detect at least two different
TREND isoforms were used for further analysis. Lengthening index was calculated
by dividing expression levels of any detectable long isoform by the levels of the
shortest isoform. Lengthening index was used for Student’s t-test (Fig. 6b, c), ROC
curves and area under curve (AUC) calculations (Fig. 7a, b). AUCs were compared
using statistical tests based on bootstrapping and DeLong’s method80.
Cox modelling. Cox proportion hazards model was built with 0.7 of training data
using MYCN or ALK expression as independent variables. Alternatively, ratios of
proximal-to-distal (APA) isoforms of neurodifferentiation operon were used in
multivariate Cox model. Modelling and validation was bootstrapped 100 times,
concordance (C)-index for model validations were plotted. To assay statistical
difference between models, a two-sided t-test was used.
Methods proteomics. SDS-PAGE and protein digestion: Forty micrograms of
protein was mixed with NuPAGE LDS buffer (Novex) and loaded onto a 4–12%
NuPage gel (Invitrogen). Gels were run at 180 V and stained with Instant Blue
Coomassie (expedeon). Each lane was cut into 10 slices per lane, which were de-
stained, alkylated with 2-iodoacetamide and digested with trypsin, as previously
described81. Peptides were extracted from the gel pieces with acetonitrile, loaded
onto STAGE tips for storage and eluted from the tips shortly before mass spec-
trometry (MS) analysis81.
Mass spectrometry: By using an EASY-nLC 1000 (Thermo Scientific) LC
system, peptides were separated at a flow rate of 400 nl/min on a self-packed
column (75 μm ID, 1.9 μm Reprosil-Pur 120 C-18AQ beads, Dr Maisch Germany)
housed in a custom-built column oven at 45 °C. Peptides were separated using
gradient of buffers A (0.1% formic acid) and B (80% acetonitrile and 0.1% formic
acid): 0–10 min 10% B, 10–55 min 10–38% B, 55–60 min 38–60% B, 60–65 min
60–95% B, 65–70 min 95% B, 70–73 min 95–3% B and 73–75 min 3% B. The
column was interfaced with a Nanospray Flex Ion Source (Thermo Scientific) to a
Q-Exactive HF mass spectrometer (Thermo Scientific). MS instrument settings
were: 1.5 kV spray voltage, full MS at 60 K resolution, AGC target 3e6, range of
300–1750m/z, max injection time 20 ms, Top 15 MS/MS at 15 K resolution, AGC
target 1e5, max injection time 25 ms, isolation width 2.2m/z, charge exclusion +1
and unassigned, peptide match preferred, exclude isotope on, dynamic exclusion
for 20 s.
Protein identification and analysis: Mass spectra were recorded with Xcalibur
software 3.1.66.10 (Thermo Scientific). Proteins were identified with Andromeda
by searching against human proteome database (71,985 proteins including
isoforms) downloaded from UniProt and were quantified with the LFQ algorithm
embedded in MaxQuant version 1.5.3.1763. The following parameters were used:
main search maximum peptide mass error of 4.5 ppm, tryptic peptides of
minimum six amino acids length with maximum two missed cleavages, variable
oxidation of methionine, protein N-terminal acetylation, fixed cysteine
carbamidomethylation, LFQ minimum ratio count of 2, matching between runs
enabled, PSM and (Razor) protein false discovery rate of 0.01, advanced ratio
estimation and second peptides enabled. Protein-protein interaction network
analysis of validated TREND-affected candidates was carried out with String-DB
(http://string-db.org/).
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Data availability
Processed TRENDseq data are available at the TREND-DB web explorer [http://
shiny.imbei.uni-mainz.de:3838/trend-db]. Raw sequencing and processed TREN-
Dseq data (underlying Figs. 1c, 2b, d, and Supplementary Figs. 2a-d,
Supplementary Figs. 3a-d and Supplementary Fig. 5a) is accessible on GEO
repository (GSE95057). The source data underlying Fig. 3b and supplementary
Fig. 6a can be made available upon reasonable request, and the source data
underlying Figs. 5f, g, 6a–c and 7a, b are available in GSE49711 and GSE49710.
Source data underlying Supplementary Fig. 7a are available in GSE25219 and data
underlying Supplementary Fig. 7d, e are available in GSE49711. Source data
underlying Fig. 7c is available in GEO GSE35493, GSE17679 and GSE17679. All
other source data can be made available upon reasonable request.
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